Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
View Patent ↗The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.
1. A fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus type 16 (HPV16), a signal peptide tPa (tissue plasminogen activator), and an immune enhancing peptide Flt3 (fms-like tyrosine kinase receptor-3) ligand for a subject, wherein the fusion polypeptide of E6 and E7 has the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 14.
2. The fusion protein according to claim 1 , wherein tPa has the amino acid sequence of SEQ ID NO: 2.
3. The fusion protein according to claim 1 , wherein the Flt3 ligand has the amino acid sequence of SEQ ID NO: 16.
4. A pharmaceutical composition for the treatment and prevention of a disease caused by a human papilloma virus in a subject, comprising the fusion protein of claim 1 and a pharmaceutically acceptable carrier.